Menu Search
Equities

Geneuro SA

GEMG:DEU

Geneuro SA

Actions
  • Price (EUR)0.04
  • Today's Change-0.001 / -2.44%
  • Shares traded0.00
  • 1 Year change-97.33%
  • Beta--
Data delayed at least 15 minutes, as of Jul 26 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Geneuro SA is a Switzerland-based clinical stage pharmaceutical company that develops treatments for autoimmune diseases, including multiple sclerosis (MS) and other diseases associated with human endogenous retroviruses (HERV). The Company's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The Company's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR-14.76m
  • Incorporated2006
  • Employees19.00
  • Location
    Geneuro SA3, Chemin du Pre-FleuriPLAN-LES-OUATES 1228SwitzerlandCHE
  • Phone+41 225524800
  • Fax+41 227945086
  • Websitehttps://www.geneuro.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.